Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares saw an uptick in trading volume on Friday . 1,157,949 shares were traded during mid-day trading, an increase of 44% from the previous session’s volume of 803,468 shares.The stock last traded at $57.26 and had previously closed at $53.36.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DNTH. Wedbush restated an “outperform” rating and issued a $46.00 price target on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, HC Wainwright lifted their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $64.43.

Dianthus Therapeutics Trading Up 0.1%

The stock has a market cap of $2.31 billion, a PE ratio of -15.34 and a beta of 1.55. The firm has a fifty day simple moving average of $43.79 and a two-hundred day simple moving average of $35.14.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insider Activity

In related news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $152,560. This represents a 96.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 216,538 shares of company stock worth $8,283,175 in the last quarter. 8.15% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Fairmount Funds Management LLC boosted its position in shares of Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after purchasing an additional 600,000 shares during the period. Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP raised its holdings in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vanguard Group Inc. lifted its position in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC boosted its stake in shares of Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.